Plant Health Care Share Discussion Threads

[geraldus] 24/6/2021 17:06

In fact looking at this of late it needs the cold Heineken.

[geraldus] 24/6/2021 16:58

rambutan2 - Cheers!

[rambutan2] 22/6/2021 23:45

geraldus, for those not young enough to appreciate your cultural reference:

[cerrito] 22/6/2021 19:10

To be honest, geradus, I was not expecting the Greenmark to move the dial.
I have yet to get my head around the impact of the big drought in Brazil both on the sugar crop and the soya planting season in a few months time and of course the overall market sentiment is not as helpful as it has been in the last months.

[oapknob1] 22/6/2021 11:23

Whose ditching

[geraldus] 14/6/2021 16:36

Was hoping the RNS stating they had received the Green Economy Mark would give this a fillip.Worked wonders( like Double Diamond)for Itaconix.

[cerrito] 14/6/2021 15:40

To me good that they have a high voter turnout at 72% for the AGM which suggests an interested shareholder base.

[cerrito] 08/6/2021 10:45

My take on the IMC meeting session of June 7 and good for them that they did it to coincide with the AGM.
Note we will have a trading statement at the end of July.
As in the past an informative meeting with questions clearly answered where they came across very upbeat.
Very confident of beating Arden’s expectations for 2021 revenue of $7.5m.Great of course but without wishing to appear curmudgeonly given all the investment the minimum increase I would have expected over the 2020 revenue outturn of $6.6m and indeed below the 2017 revenue of $7.7m.
US corn had a good 2020 and doing well so far this year even with a bad drought. Speciality going well in California and even better in Oregon and Washington. Going well in Europe in fruit and citrus and a return of the amenity market. A distributor about to the signed up-not clear if that would be EU wide. However, Mexico a challenge especially with vegetables in the Northern states . Drought and COVID are headwinds in Brazil sugarcane.

They were if anything more cautious of Saori sales this year, if for no other reason that supply is tight. The key for them is to get sales into a broad range of growers.No questions asked as to where they stand on mass manufacturing of that product. Discussions with a Brazilian distributor continue but was not the focus of questioning. Covid has been a hindrance. I detected that slightly more cautious than in previous IMC meetings of the speed of take up of Sauri. Also said that given the sugar cane was a 16moth crop cycle, getting market acceptance is also protracted. While the focus in Brazil of Sauri/279 is on soya where disease is a big issue, in the US it will be on fruit and speciality as disease is not such a big issue for US soya. Made a comment that in Brazil finding that Sauri is effective for other diseases than Asian rust and they are doing work on this.
Confirmed that delay- driven by tactical considerations- in submission for registration of 949 in the US from mid 2021 to year end 2021. Brazil next year.
Repeated what they said in a previous meeting about the long payment terms demanded/expected by Brazilian growers. For sugar cane much of these extended terms are shouldered by the distributor and they have set up factoring arrangements with the Brazilian banks for Soya.
All seems good but there is a need for patience.

[dlem] 14/5/2021 16:52

Some significant buys today!

[cerrito] 23/4/2021 17:10

Not terribly impressed.
I saw that the list of significant shareholders has not been changed since June 20 and of course there has been a change following the recent equity issue.
I emailed the IR contact as per website and that bounced back.
I the tried Arden without success.
I then phoned the company in the US and could not speak to a human.
Will try on Monday

[cerrito] 23/4/2021 16:56

Had a look through the RNS today and for me nothing unexpected as much of this had been covered in their IMC events.
The only thing is that my notes of the recent IMC sessions says they expected to file for 949 in the US mid year and in their discussion of 949 in the RNS there was no mention of this.
Any of you have any view?

[kenwright] 19/4/2021 20:48

Getting the word out on the street again....

[geraldus] 15/4/2021 17:45

Somebody offloading in 50k chunks.With all the cash they have raised at prices of 8p/10p/14p (not forgetting 20p),profit taking always a temptation.They did say they don't want raise anymore money but......Least ways it actually shot up after the last whipround.

[pugugly] 15/4/2021 17:16

So what bad news is leaking? For every step forward.. 2 steps back.. Could this be yet another UK agri-tech on the way to the compost heap?

[geraldus] 15/4/2021 16:16

Quite a drop after 4pm on persistent selling.Had a few.Gla.

[dlem] 06/4/2021 20:28

1,029,000 share trade after close!

[pr4w2b0y] 29/3/2021 20:10

One of the Qs was who are PHC competitors. These co names keep cropping up;

Syngenta (Switzerland)
Isagro (Italy)
BASF GmbH
Plant Health Care (US)
Arysta LifeScience (US)
Nihon Nohyaku Co., Ltd. (Japan)
Meiji Seika (Japan)
Certis (US)
Gowan (US)
Futureco Bioscience (Spain)
NutriAg (Canada)
Eagle Plant Protect Pvt. Ltd. (India)

Given the size of these co they are probable JVs & MAs.

[pr4w2b0y] 28/3/2021 17:45

*aren't they still underpinned by their Mexican business, I guess they want to move to asset light model.

hxxp://news.agropages.com/News/NewsDetail---40015.htm

[cerrito] 27/3/2021 09:28

Very much one of the better IMC calls I have listened to with a good presentation and good questions and well worth a listen.
Some of the main points for me.
One was a question posed on a dual listing which we were told is not on the cards at the moment but what they are looking at seriously is an US OTC listing following what other European companies are doing and reflects the fact that their shares undervalued in a US context. No timescale given.
He was asked why no retail/Primary Bid offer in the recent equity raise. We did not get a clear answer but we were told that one thing they wanted to achieve was to balance out the shareholder register with the combined holdings of Ospraie and Griffiths over 50%. Both had agreed to stand aside in this fundraising and hopefully there will be more liquidity now in the shares. I applaud this but still not clear to me why there was no primary bid mechanism.
He was asked why given that it was oversubscribed they did not raise more money. I did not get a very clear answer . We were told that they spend the cash very carefully but recognized that pretec investment is growing-my notes tell me $2.7m last year to a projected 2022 figure of $5m. I a m comfortable with the amount raised as it gives them enough for their identified requirements . I go on the basis that another fund raising may well be required in 18/24 months and touch wood the share price will be higher.
He cautioned us not to expect big sales in Brazil soya this year. He said that the authorization from the Brazilian authorities came through faster than they had predicted so do not have all their ducks in a row.Their product is used to treat the seeds before planting ie in the August/October period depending on where they are in Brazil. Sales will thus be only a few months away and they have yet to finalize their discussions with potential distributor- at this stage looking to have 1 or 2 national ones. We were reminded that they do not have their manufacturing properly set up and will be using Penn State. Emphasized that when they are up and running they will not be doing their own manufacturing and are in discussions with 2 toll manufacturers.
Where does this leave us?
On the assumption that the US/£ FX rate is in the area of 1.35, I anticipate the share price in the 14/18 area for the near term. I think the key financial figures for 2020 have been well trailed so do not see the AR changing the price much. The mid year filing for authorization of 949 could provoke some movement and the interim figures hopefully will. Having the shares OTC in the US would move the dial.

[dlem] 24/3/2021 17:24

More big transactions printed after hours. 2 x 2.6m share trades.

[dlem] 22/3/2021 17:19

17:07 - 1,279,643 trade @ 18.4p. Somebody was impressed by the shareholder presentation!

[vsb234] 22/3/2021 11:10

RNS Number : 9378S
Plant Health Care PLC
22 March 2021


Investor Presentation

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce that Dr. Christopher Richards, CEO, and Jeffrey Tweedy, COO, will provide a live presentation via the Investor Meet Company platform on the 26th of March, 2021, at 2:00pm GMT.

The Company is committed to ensuring that there are appropriate communication structures for all elements of its shareholder base so that its strategy, business model and performance are clearly understood.

Highlights

- The online presentation is open to all existing and potential shareholders.

- Questions can be submitted pre-event via your IMC dashboard up until 9am the day before the meeting or any time during the live presentation via the "Ask a Question" function. Although the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market. Responses to the Q&A from the live presentation will be published at the earliest opportunity on the Investor Meet Company platform.

- Investors can sign up to Investor Meet Company for free and add to meet Plant Health Care plc via: hxxps://www.investormeetcompany.com/plant-health-care-plc/register-investor

Investor feedback can also be submitted directly to management post-event to ensure the Company can understand the views of all elements of its shareholder base. Investors who already follow Plant Health Care plc on the Investor Meet Company platform will automatically be invited.

[vsb234] 22/3/2021 11:08

Arden Partners says there is ‘significant value’ in Plant Health Care’s PREtec platform (www.voxmarkets.co.uk/articles/arden-partners-says-there-is-significant-value-in-plant-health-care-s-pretec-platform-a2d3732)

New research from UK-based institute Arden Partners has highlighted the ‘significant value’ in Plant Health Care’s (PHC) technology platform, PREtec, within the global agriculture industry.

PHC, which provides patent-protected biological products to global agricultural markets, announced its intention to raise up to US$10 million on Thursday through an oversubscribed placing at a price of 14p, a c.12% discount to its closing mid-market price on Wednesday.

The funds will be used to accelerate the development of products from the PREtec platform, seek regulatory approval in Europe, support the expansion of the group’s commercial business which it said is ‘performing very well’, as well to strengthen PHC’s balance sheet.

The group’s PREtec technology platform works by inducing natural defensive and metabolic responses in crop plants, helping to reduce harm from stresses during the growing season.

To date, the company has invested more than US$20 million over the last eight years into its PREtech technology platform, with the first commercial product launch anticipated in 2H21.

In a research note released yesterday, analysts at Arden said the group’s recent newflow indicates that its PREtec technology is continuing to gain traction, and with further funding now secured, ‘investors should focus on execution and growth across the Group’s portfolio.’

It said recent research on PREtec confirms ‘huge market opportunities for the products with demand built on robust, demonstrable efficacy and excellent sustainable credentials which align very well with the global ag industry’s current practices and overall direction of travel.’

It said its discussions with PHC’s distribution partners indicate excellent support for the products with many medium-term expansion opportunities built on patented technology.

As a result of PHC’s recent positive newsflow, Arden has updated its earnings estimates in order to reflect the new equity and increased expenditure, as well as upgraded its medium-term revenue forecasts which it said reflects the added investment and expenditure.

The research firm said it anticipates increased visibility through 2021 as the exact phasing and targeting of PHC’s resources takes shape. Meanwhile, it highlighted that the increased expenditure ‘should ultimately raise value creation in the medium term’ in its view.

Shares in Plant Health Care have increased by nearly 30% since the beginning of 2021. The stock saw a strong start to the year after PH279 (now known and branded as Saori) became the first product from its PREtec platform to receive federal approval for sale in Brazil. Shares in the stock ticked up by 3.74% this morning to 18.31p following the fundraising.

London-listed Plant Health Care is a leading provider of proprietary agricultural biological products and technology solutions focused on improving crop performance.

Its commercial business is driven by sales of Harpin αß, a recombinant protein which acts as a powerful biostimulant, promoting the yield and quality of crops. PHC sells the proprietary soil treatment Myconate in selected countries and sells both Harpin αß and Myconate through specialist distributors globally. In Mexico, PHC distributes third-party biological products.

PHC utilises its PREtec platform to generate numerous products and it is focusing on three products targeting very large market opportunities with a value of more than $5bn.

The Group said these products are currently under evaluation with six potential commercial partners. Meanwhile, PHC also continues to evaluate further candidate products from its robust pipeline of development candidates for additional crops and indications.

In a trading update released in January 2021, the Group reported robust in-market sales growth of Harpin αβ with in-market sales in Brazilfor sugarcane coming in at three times those of 2019, while in-market sales to corn came in at 1.8 times higher than the prior year.

Meanwhile, the Group hailed its progress in bringing the first products from the PREtec platform to market. It highlighted it is planning for initial commercial launch in Brazil during the second half of 2021.